托弗森用于SOD1肌缩侧面硬化症:系统性审查和元分析
Abdullah Ashraf Hamad1, Ibraheem M Alkhawaldeh2,3, Abdulqadir J Nashwan4,5
1Faculty of Medicine, Menoufia University, Menoufia, 32511, Egypt. abdullah.hamad744@gmail.com.
概括
托弗森有效地降低了SOD1和神经纤维光链水平在SOD1相关的肌缩侧面硬化症 (ALS) 患者. 这种反感性寡核酸在减缓疾病进展方面表现有前途,为ALS提供了向的治疗选择.
科学领域:
- 神经学 神经学
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 肌缩侧面硬化症 (ALS) 是一种进展性神经退行性疾病.
- SOD1基因的突变是家族性ALS的已知原因之一.
- 托弗森是一种经批准的对SOD1-ALS的抗感性寡核酸治疗方法.
研究的目的:
- 系统地审查和元分析托弗森在治疗SOD1相关的ALS中的安全性和有效性.
- 综合目前关于托弗森对疾病生物标志物和进展的影响的证据.
主要方法:
- 对临床试验,观察性研究和案例研究进行全面的数据库搜索.
- 使用随机效应模型对符合条件的研究进行元分析.
- 包括12项研究,其中包括195名用tofersen治疗的患者.
主要成果:
- 托弗森显著降低了SOD1和血NfL水平.
- 对RCT的元分析显示,ALSFRS-R得分下降速度较慢,预测生命能力缓慢.
- 前后元分析表明,ALS进展率显著下降.
结论:
- 托弗森在减少SOD1-ALS.中的关键生物标志物 (SOD1,NfL) 中显示出有效性.
- 该疗法显示出减缓疾病进展的潜力,功能和呼吸系统测量证明了这一点.
- 托弗森代表了对SOD1突变的个体有前途的向治疗策略.
相关概念视频
Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...


